Beta-2 Glycoprotein 1 Antibodies, IgG, IgM and IgA

2002569
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive

Ordering Recommendation

When antiphospholipid syndrome (APS) is strongly suspected, preferred panel is Beta-2 Glycoprotein 1 Antibodies, IgG and IgM (0050321).

Mnemonic

B2GPI PAN3

Methodology

Semi-Quantitative Enzyme-Linked Immunosorbent Assay

Performed

Sun-Sat

Reported

1-2 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube.

Specimen Preparation

Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or other body fluids. Contaminated, hemolyzed, grossly icteric, or severely lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Reference Interval

Test Number
 Components
 Reference Interval
  B2Glycoprotein 1, IgG Antibody Effective November 15, 2021
<=20 SGU
  B2Glycoprotein 1, IgM Antibody Effective November 15, 2021
<=20 SMU
  B2Glycoprotein 1, IgA Antibody Effective November 15, 2021
<=20 SAU

Interpretive Data

The persistent presence of IgG and/or IgM beta 2 glycoprotein I (B2GPI) antibodies is a laboratory criterion for the diagnosis of antiphospholipid syndrome (APS). Persistence is defined as moderate or high levels of IgG and/or IgM B2GPI antibodies detected in two or more specimens drawn at least 12 weeks apart (J Throm Haemost. 2006;4:295-306). B2GPI results greater than 20 SGU (IgG) and/or SMU (IgM) are considered positive based on the cutoff values established for this test. International reference materials and consensus units for anti-B2GPI antibodies have not been established (Clin Chim Acta. 2012;413(1-2):358-60; Arthritis Rheum. 2012;64(1):1-10.); results can be variable between different commercial immunoassays and cannot be compared. Strong clinical correlation is recommended for a diagnosis of APS. Low positive IgG and IgM B2GPI antibody levels should be interpreted in light of APS-specific clinical manifestations and/or other criteria phospholipid antibody tests.

Compliance Category

FDA

Note

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
11/15/2021
X
N/A

CPT Codes

86146 x3

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0050322 B2Glycoprotein 1, IgG Antibody 44448-9
0050323 B2Glycoprotein 1, IgM Antibody 44449-7
0050324 B2Glycoprotein 1, IgA Antibody 21108-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Anti-B2-Glycoprotein 1
  • Anti-B2-Glycoprotein I
  • Anti-B2-GP 1
  • Anti-B2-GP I
  • Anti-B2-GP1
  • Anti-B2-GPI
  • Anti-beta-2 glycoprotein 1
  • Anti-Beta-2-Glycoprotein I
  • Apolipoprotein H
  • B2-glycoprotein 1 antibodies
  • B2GP Antibodies
  • B2GP1
  • B2GPI IgG, IgM, IgA
  • Beta 2 GP1 Ab IgA
  • Beta 2 GP1 Ab IgG
  • Beta 2 GP1 Ab IgM
  • Beta 2GP1 Ab
  • Beta-2 Glycoprotein 1
Beta-2 Glycoprotein 1 Antibodies, IgG, IgM and IgA